Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers - current evidence and future directions.

Front Oncol · 2022 · PMC9556664 · PMID 36248993

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the post-hoc analysis of 133 patients with RAS/BRAF -WT CRC, ctDNA tracking showed a trend towards a higher prevalence of acquired mutations associated with resistance to EGFR antibody in patients (n = 11; 15.3%) randomized to the bevacizumab arm than patients in the cetuximab arm (n = 5; 8.2%) (OR = 2.0; P = 0.29).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.